2017
A critique of the “ultra‐high risk” and “transition” paradigm
van Os J, Guloksuz S. A critique of the “ultra‐high risk” and “transition” paradigm. World Psychiatry 2017, 16: 200-206. PMID: 28498576, PMCID: PMC5428198, DOI: 10.1002/wps.20423.Peer-Reviewed Original ResearchClinical high riskUltra-high riskCommon mental disordersMental disordersPsychotic experiencesCHR researchHigh-risk approachMental health problemsPublic health perspectiveFalse-positive findingsTransdiagnostic expressionClinical picturePoor outcomePoor prognosisFunctional outcomeBaseline differencesHigh riskOmega-3Health problemsPositive findingsEpidemiological researchDiagnostic shiftUHR sampleYoung individualsHealth perspective
2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial
Tek C, Guloksuz S, Srihari VH, Reutenauer EL. Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC Psychiatry 2013, 13: 176. PMID: 23805859, PMCID: PMC3702521, DOI: 10.1186/1471-244x-13-176.Peer-Reviewed Original ResearchConceptsSevere mental illnessEfficacy of naltrexoneWeight gainOutcome measurementsHealth problemsMental illnessGreater New Haven areaTumor necrosis factor alphaWeight lossCurrent available medicationsPlacebo-controlled trialHigh-sensitivity CRPOpioid receptor antagonistSecondary outcome measuresSerum lipid profilePrimary outcome measurementBody mass indexD2 receptor blockadeEffects of naltrexoneNovel pharmacological optionsNecrosis factor alphaDoses of naltrexoneMajor health problemRates of obesitySignificant weight loss